secwatch.observer — SEC 8-K summary
======================================

Issuer:     IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
CIK:        0001425205
Form:       8-K
Filed at:   2026-07-02T21:01:00+00:00
Accession:  0001104659-26-080409
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Iovance updates corporate presentation; guides FY26 revenue $350M-$370M, Q2 $86M-$88M
--------------------------------------------------------------------------------

- Q2 2026 revenue guidance of $86M-$88M; FY26 revenue guidance $350M-$370M; ~45% YoY quarterly growth.
- Amtagvi commercial launch: >90 treatment centers, >1,500 patients treated; 5-year durability data: 31.4% ORR, 19.7% OS.
- Lifileucel in NSCLC: 25.6% ORR, mDOR not reached at 25.4 months; Fast Track Designation; potential launch 2H27.
- Soft tissue sarcoma Phase 2 registrational trial to commence 2Q 2026; 50% ORR in early data.
- Cash $319M as of 3/31/26; manufacturing capacity up to 5K patients/year; broad payer coverage.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1425205/000110465926080409/0001104659-26-080409-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1425205/000110465926080409/tm2618989d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-080409

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer